← Leaderboards
Suzanne Ostrand-Rosenberg
University Of Maryland Balt Co Campus
$5,482,426
Attributed
$6,494,754
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $624.2K · FY2006–17$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$6,494,754 · 4
By mechanism
R01$6,494,754 · 4
Top collaborators
- Catherine C. Fenselau5 shared
- David Fushman5 shared
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorT-LymphocyteCellsImmuneGrantPreventBaseSiteCancer VaccinesDisseminated Malignant NeoplasmPrimary NeoplasmGenesNeoplastic CellImmunityNeoplasm MetastasisCd8b1 GeneMass Spectrum AnalysisMhc Class Ii AntigenMetastasisMyelogenousAntigen PresentationMediatingMyeloid CellsCancer Patient
Grant awards (27)
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells$362,818
R01 · FY2017 · GM
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells$362,818
R01 · FY2016 · GM
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells$362,818
R01 · FY2015 · GM
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells$375,608
R01 · FY2014 · GM
Ubiquitinated Proteins in Exosomes of Immune Suppressive Myeloid Cells$54,430
R01 · FY2014 · GM
Cell-based tumor vaccines targeting CD4+ T lymphocytes$263,130
R01 · FY2011 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$58,071
R01 · FY2011 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$271,147
R01 · FY2010 · CA · contact PI
Tumor-induced immune suppression.$253,359
R01 · FY2010 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$56,553
R01 · FY2010 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$271,170
R01 · FY2009 · CA · contact PI
Tumor-induced immune suppression.$253,359
R01 · FY2009 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$32,853
R01 · FY2009 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$370,820
R01 · FY2008 · CA · contact PI
Tumor-induced immune suppression.$253,359
R01 · FY2008 · CA · contact PI
Cell-based tumor vaccines targeting CD4+ T lymphocytes$270,853
R01 · FY2007 · CA · contact PI
Tumor-Induced immune suppression$253,359
R01 · FY2007 · CA · contact PI
Tumor-induced immune suppression$260,925
R01 · FY2006 · CA · contact PI
Tumor cell antigen presentation to CD4 + T lymphocytes$266,468
R01 · FY2004 · CA
Tumor cell antigen presentation to CD4 + T lymphocytes$266,584
R01 · FY2003 · CA
CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES$260,003
R01 · FY2003 · CA
Tumor cell antigen presentation to CD4 + T lymphocytes$267,150
R01 · FY2002 · CA
CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES$252,864
R01 · FY2002 · CA
Tumor cell antigen presentation to CD4 + T lymphocytes$266,585
R01 · FY2001 · CA
CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES$246,764
R01 · FY2001 · CA
CELL BASED TUMOR VACCINES TARGETING CD4+ T LUMPHOCYTES$240,886
R01 · FY2000 · CA
ENHANCING TUMOR IMMUNITY BY CLASS II GENE TRANSFECTION$40,000
R01 · FY2000 · CA